Pineapple
Just Smile.
- Reaction score
- 576
CHICAGO, July 29 -- An old drug for urinary-tract infections, methylene blue (Urolene Blue), may hold the key to a therapy that can slow the progress of Alzheimer's disease for as long as 19 months, researchers here reported.
After 24 months of treatment with 60 mg three times a day of methylthioninum chloride (rember), patients with moderate Alzheimer's disease achieved a treatment effect that "was twice the effect seen with donepezil (Aricept)," said Claude Wischik, Ph.D., of the University of Aberdeen in Scotland.
The drug called rember is a formulation of methylene blue made by TauRx Therapeutics, and Dr. Wischik is founder and chairman of TauRx Therapeutics. The drug attacks tau, which promotes tangles, as opposed to amyloid plaques.
After 50 weeks, pooled data from mild and moderate Alzheimer's disease patients indicated an 81% reduction in the rate of cognitive decline versus controls, which was a difference of 6.8 units on the Alzheimer's Disease Assessment Scale, that was highly significant (P<0.0001)
After 24 months of treatment with 60 mg three times a day of methylthioninum chloride (rember), patients with moderate Alzheimer's disease achieved a treatment effect that "was twice the effect seen with donepezil (Aricept)," said Claude Wischik, Ph.D., of the University of Aberdeen in Scotland.
The drug called rember is a formulation of methylene blue made by TauRx Therapeutics, and Dr. Wischik is founder and chairman of TauRx Therapeutics. The drug attacks tau, which promotes tangles, as opposed to amyloid plaques.
After 50 weeks, pooled data from mild and moderate Alzheimer's disease patients indicated an 81% reduction in the rate of cognitive decline versus controls, which was a difference of 6.8 units on the Alzheimer's Disease Assessment Scale, that was highly significant (P<0.0001)
Last edited by a moderator:
